Gavin R Graff

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. doi request reprint Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period cros
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Penn State Medical School, Department of Pediatrics, Hershey, Pennsylvania 17033 0850, USA
    Clin Ther 32:89-103. 2010
  2. doi request reprint Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Clin Drug Investig 30:351-64. 2010

Detail Information

Publications2

  1. doi request reprint Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period cros
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Penn State Medical School, Department of Pediatrics, Hershey, Pennsylvania 17033 0850, USA
    Clin Ther 32:89-103. 2010
    ..The US Food and Drug Administration regulations now require all PERT products to undergo clinical efficacy and safety studies before they can be considered for marketing approval...
  2. doi request reprint Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study
    Gavin R Graff
    Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
    Clin Drug Investig 30:351-64. 2010
    ..In this study in children aged <7 years with EPI due to CF, the new formulation pancrelipase delayed-release capsules (CREON) were clinically comparable with standard therapy in terms of safety, tolerability and efficacy...